Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BG00011 (STX-100) in Idiopathic Pulmonary Fibrosis
NCT01371305Phase 2Completed
- Sponsor
- Biogen
- Start
- Jul 2012
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of STX-100 in idiopathic pulmonary fibrosis (IPF), sponsored by Biogen. Started Jul 2012; status: completed.
02
Drugs
STX-100
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01371305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371305.